Generic firms club together to take on big pharma patents The Pharma Letter
The end of a drug’s exclusivity period can result in expensive patent litigation, and IP lawyer Kent Walker has identified an emerging trend that could present.
Generic firms club together to take on big pharma patents The Pharma Letter
The end of a drug’s exclusivity period can result in expensive patent litigation, and IP lawyer Kent Walker has identified an emerging trend that could present.